Potential targets for cancer therapy include efferocytosis-related genes and pathways, such as phosphatidylserine, TYRO3, MerTK, indoleamine-2,3-dioxygenase 1, membrane-linked protein V, CD 47, TGF-β, and IL-10 [45]. Here, MERTK is linked to cancer.